Rozlytrek 100 mg hard capsules

DRUG4 trials

Sponsors

F. Hoffmann-La Roche AG, Oslo University Hospital HF, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Conditions

Advanced solid tumorCancerMultiple myelomaNon-Hodgkin lymphomaNon-small cell lung cancer with ROS proto-oncogene 1Solid tumorsT-cell prolymphocytic leukemiareceptor tyrosine kinase (ROS1) gene rearrangements

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruitingCTIS2023-507418-28-00

F. Hoffmann-La Roche AGSolid tumors

Start: 2021-03-15Target: 407Updated: 2025-12-09

Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway

RecruitingCTIS2023-507894-16-00

Oslo University Hospital HFCancer

Start: 2021-04-01Target: 6000Updated: 2026-01-22

Phase 3

Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements with and Without Central Nervous System Metastases

RecruitingCTIS2023-507494-18-00

F. Hoffmann-La Roche AGNon-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements

Start: 2021-09-24Target: 91Updated: 2026-01-20

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01